Association Between Circulating Inflammatory Proteins and Clinical Prognosis in Chinese Patients with EGFR Mutation–Positive Non–Small Cell Lung Cancer
Rui Guan,Anqi Lin,Peng Luo,Jian Zhang
DOI: https://doi.org/10.1016/j.jtho.2019.05.027
IF: 20.121
2019-01-01
Journal of Thoracic Oncology
Abstract:We read with interest the article titled “Circulating Inflammation Proteins Associated with Lung Cancer in African Americans” by Claire et al., in which they revealed that elevated interleukin-6 (IL-6) and C-reactive protein (CRP) levels were associated with a poor prognosis in patients with lung cancer.1Meaney C. Mitchell K.A. Zingone A. et al.Circulating inflammation proteins associated with lung cancer in African American. J Thorac Oncol.. 2019; 14: 1192-1203Google Scholar Given that differences in tumor biology might affect the universality of results across populations, we collected relevant data from the Zhujiang Hospital of Southern Medical University (Table 1), referring to the inclusion and exclusion criteria of this article,1Meaney C. Mitchell K.A. Zingone A. et al.Circulating inflammation proteins associated with lung cancer in African American. J Thorac Oncol.. 2019; 14: 1192-1203Google Scholar to explore the effects of IL-6 and CRP levels on the prognosis of patients with lung cancer in the People's Republic of China.Table 1Characteristics of Patients with Lung CancerCharacteristicValue (N = 372)EGFR-Positive (n = 38)EGFR-Negative (n = 30)p ValueMean age, y, ± SD63.94 ± 12.0163.29 ± 12.9863.13 ± 12.640.960Sex, n (%)0.008 Male261 (70.16%)17 (44.74%)23 (76.67%) Female111 (29.84%)21 (55.26%)7 (23.33%) Missing0 (0.00%)0 (0.00%)0 (0.00%)Body mass index, n (%)0.116 Underweight (<18.5 kg/m2)55 (14.78%)2 (5.26%)5 (16.67%) Healthy (18.5–25 kg/m2)198 (53.23%)25 (65.79%)17 (56.67%) Overweight (25–30 kg/m2)45 (12.10%)4 (10.53%)1 (3.33%) Obese (>30 kg/m2)5 (1.34%)1 (2.63%)1 (3.33%) Missing69 (18.55%)6 (15.79%)6 (20.00%)Smoking status, n (%)0.561 Never199 (53.49%)19 (50.00%)13 (43.33%) Former59 (15.86%)6 (15.79%)4 (13.33%) Current102 (27.42%)11 (28.95%)13 (43.33) Missing12 (3.23%)2 (5.26%)0 (0.00%)Median pack-years (P25–P75)40.00 (24.38–59.25)10.00 (5.00–50.00)40.00 (27.00–42.50)0.221History of emphysema, bronchitis, asthma, or tuberculosis, n (%) No246 (66.13%)28 (73.68%)16 (53.33%) Yes126 (33.87%)10 (26.32%)14 (46.67%) Missing0 (0.00%)0 (0.00%)0 (0.00%)Stage, n (%)0.373 I60 (16.13%)5 (13.16%)3 (10.00%) II39 (10.48%)2 (5.26%)4 (13.33%) III76 (20.43%)7 (18.42%)8 (26.67%) IV179 (48.12%)24 (63.16%)15 (50.00%) Missing18 (4.84%)0 (0.00%)0 (0.00%)Histologic subtype, n (%)0.737 Adenocarcinoma220 (59.14%)28 (73.68%)21 (70.00%) Squamous84 (22.58%)10 (26.32%)9 (30.00%) Other45 (12.10%)0 (0.00%)0 (0.00%) Missing23 (6.18%)0 (0.00%)0 (0.00%)Median CRP level, mg/L (P25–P75)20.65 (4.13–61.45)17.15 (2.48–53.03)41.10 (6.46–93.43)0.063Median IL-6 level, pg/mL (P25–P75)20.95 (8.93–51.25)19.40 (7.35–52.08)33.75 (14.38–53.15)0.088P25–P75, 25th percentile to 75th percentile; CRP, C-reactive protein; IL-6, interleukin-6. Open table in a new tab P25–P75, 25th percentile to 75th percentile; CRP, C-reactive protein; IL-6, interleukin-6. Studies have shown that the prevalence of EGFR mutations in patients with NSCLC is approximately 19% in Western countries, whereas the corresponding incidence in Asia is approximately 48%.2Dearden S. Stevens J. Wu Y.L. Blowers D. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap).Ann Oncol. 2013; 24 (2371–2371)Google Scholar Considering such differences among populations, a subgroup analysis was designed on the basis EGFR testing results (mutant versus wild-type) determined by using the amplification refractory mutation system method. Of the 372 patients enrolled, 68 patients with NSCLC underwent EGFR mutation testing, and the results showed 38 with an EGFR mutation and 30 with wild-type EGFR. According to the medians of the inflammatory proteins (IL-6 and CRP), we divided the 372 patients into corresponding high-value and low-value groups. A survival analysis based on IL-6, CRP, and a combined CRP and IL-6 classifier showed that for all patients, elevated inflammatory protein levels predicted a poor prognosis (Fig. 1A–C), which was consistent with the results of Claire et al. In the subgroup analysis, we observed an interesting phenomenon: in patients with EGFR-mutated NSCLC, the results were in accordance with the overall results (Fig. 1D–F), whereas in patients with EGFR wild-type NSCLC, however, no significant differences were observed (Fig. 1G–I). It has been reported that elevated IL-6 levels autocrined by cancer cells because of a mutation in the EGFR kinase domain or that existing in the tumor microenvironment leads to overexpression of signal transducer and activator of transcription 3 through activation of the gp130/Janus kinase 1 pathway or IL-6R/Janus kinase 1/signal transducer and activator of transcription 3 pathway, which may further promote secondary resistance to EGFR tyrosine kinase inhibitors in patients with NSCLC with mutant EGFR.3Ray K. Ujvari B. Ramana V. Donald J. Cross-talk between EGFR and IL-6 drives oncogenic signaling and offers therapeutic opportunities in cancer.Cytokine Growth Factor Rev. 2018; 41: 18-27Google Scholar, 4Kim S.M. Kwon O.J. Hong Y.K. et al.Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.Mol Cancer Ther. 2012; 11: 2254-2264Crossref PubMed Scopus (159) Google Scholar Therefore, we speculate that the differences in IL-6 levels may further affect the process of drug resistance by regulating the tumor microenvironment and that patients with elevated IL-6 levels may be more prone to earlier development of secondary drug resistance, thus widening the survival gap between those with high and low IL-6 levels. In addition, we would like to conjecture that IL-6 inhibitors in combination with EGFR tyrosine kinase inhibitors may enhance the efficacy of targeted therapy. In this study, we performed an EGFR subgroup analysis, only a few which have been conducted previously, and found that the survival differences between individuals with low and high levels of inflammatory proteins (IL-6 and CRP) may be more significant in patients with NSCLC with EGFR mutation than in those with wild-type EGFR. Given the small number of patients who underwent EGFR examination and the diverse genetic background among populations, additional studies involving a large number of samples and diverse ethnic groups are necessary. The authors thank the staff of YiduCloud Technology Ltd Beijing, China and Shanghai Lejiu Healthcare Technology Co., Ltd, China for providing technical support on the big-data intelligence platform.